Rallybio (RLYB) Income from Continuing Operations (2020 - 2026)
Rallybio (RLYB) posted Income from Continuing Operations of 8278000.0 for Q1 2026, down 41.46% sequentially from 5852000.0 in Q4 2025, and up 6.48% YoY from 7773907.91 in Q1 2025.
Rallybio (RLYB) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Rallybio has reported Income from Continuing Operations for 7 years, with the latest figure at 8278000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 6.48% year-over-year to 8278000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7530000.0 (up 83.65% YoY) and the FY2025 annual result came in at 8104000.0, up 85.41% from the prior year.
- Income from Continuing Operations slipped to 8278000.0 in Q1 2026 per RLYB's latest filing, from 5852000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 16016000.0 in Q3 2025 and troughed at 19629000.0 in Q4 2023.
- A 5-year average of 12354117.65 and a median of 15749000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations sank 84.88% in 2022, then surged 247.9% in 2025.
- Over 5 years, Income from Continuing Operations stood at 15989000.0 in 2022, then dropped by 22.77% to 19629000.0 in 2023, then soared by 45.93% to 10614000.0 in 2024, then soared by 44.87% to 5852000.0 in 2025, then sank by 41.46% to 8278000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 8278000.0, 5852000.0, and 16016000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | 43.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.67 Mn |
| Mar 31, 2026 | -8.28 Mn |
| Dec 31, 2025 | -5.85 Mn |
| Sep 30, 2025 | 16.02 Mn |
| Jun 30, 2025 | -9.42 Mn |
| Mar 31, 2025 | -8.85 Mn |
| Dec 31, 2024 | -10.61 Mn |
| Sep 30, 2024 | -10.83 Mn |
| Jun 30, 2024 | -15.75 Mn |
| Mar 31, 2024 | -18.34 Mn |
| Dec 31, 2023 | -19.63 Mn |
| Sep 30, 2023 | -17.73 Mn |
| Jun 30, 2023 | -18.41 Mn |
| Mar 31, 2023 | -16.76 Mn |
| Dec 31, 2022 | -15.99 Mn |
| Sep 30, 2022 | -18.24 Mn |
| Jun 30, 2022 | -17.25 Mn |
| Mar 31, 2022 | -14.11 Mn |
| Dec 31, 2021 | -12.19 Mn |
| Sep 30, 2021 | -9.86 Mn |